BDNF

BDNF Informations sur la molécule

Nom anglais	Brain-derived neurotrophic factor	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	8	Alias de la cible	Brain-Derived Neurotrophic Factor，Abrineurin，ANON2，Brain Derived Neurotrophic Factor，BULN2，ProBDNF，Neurotrophin
Phase de R&D la plus avancée	Phase 3 Clinical

Nom anglais	Brain-derived neurotrophic factor
Alias de la cible	Brain-Derived Neurotrophic Factor，Abrineurin，ANON2，Brain Derived Neurotrophic Factor，BULN2，ProBDNF，Neurotrophin
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	8
Phase de R&D la plus avancée	Phase 3 Clinical

BDNF Liste de produits

Attribut
Protein (4)
Bibliothèque de produits
En ligne (4)
Espèces
Human (4)
Étiquette
Tag Free (4)
Marqueur
Unconjugated (4)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
BDF-H5116	Human	E. coli	Human BDNF / Abrineurin Protein (E. coli), premium grade	Ajouter au panier
BDF-H5117	Human	E. coli	Human BDNF / Abrineurin Protein (E. coli), Research Grade	Ajouter au panier
BDF-H5219	Human	HEK293	Human BDNF / Abrineurin Protein (HEK293), premium grade	Ajouter au panier
GMP-BDFH15	Human	E. coli	GMP Human BDNF Protein (E. coli)	Ajouter au panier

Quantité totale4

BDNFContexte de la molécule

Brain-derived neurotrophic factor (BDNF) along with nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) are members of the neurotrophin family of trophic factors. The neurotrophins play essential roles in the development, survival, and function of a wide range of neurons in both the peripheral and central nervous systems. The neurotrophins interact with two cell surface receptors, the low affinity P75 receptor and the Trk family of high affinity tyrosine kinase receptors. NGF preferentially binds TrkA, BDNF and NT4/5 bind TrkB, and NT-3 binds TrkC (and TrkA to a lesser extent).

BDNFAlias de la molécule

BDNF,ANON2,BULN2,Abrineurin

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Tetramethylpyrazine Nitrone		Phase 3 Clinical	Jinan University	Amyotrophic Lateral Sclerosis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ischemic Stroke	Details
JS1-1-01	JS1-1-01	Phase 3 Clinical	Tianjin Tasly Pharmaceutical Co Ltd	Depression; Depressive Disorder; Depressive Disorder, Major	Details
ACT-01	ACT-01; OCS-05; BN-201; G-79	Phase 2 Clinical	Promius Pharma	Keratosis, Actinic; Optic Neuritis	Details
Aldifen	MP101; NSC-1532; MP-101	Phase 2 Clinical	Mitochon Pharmaceuticals	Amyotrophic Lateral Sclerosis; Huntington Disease; Multiple Sclerosis	Details
ALTO-100	ALTO-100	Phase 2 Clinical	Alto Neuroscience Inc	Bipolar I Disorder; Bipolar II Disorder; Depressive Disorder, Major; Stress Disorders, Post-Traumatic	Details
AC-102	AC-102	Phase 2 Clinical	AudioCure Pharma GmbH	Hearing Loss, Sensorineural; Hearing Loss, Sudden; Tinnitus	Details
Laquinimod Sodium	TV-5600; ABR-215062; SAIK-MS	Phase 1 Clinical	Active Biotech Ab	Arthritis; Crohn Disease; Eye Diseases; Huntington Disease; Lupus Nephritis; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Uveitis	Details
AAV2-BDNF gene therapy (University Of California San Diego)		Phase 1 Clinical	University Of California San Diego	Alzheimer Disease; Cognitive Dysfunction	Details